Natdac
Natdac (Daclatasvir 30/60 mg) — Natco pan-genotypic NS5A inhibitor for chronic hepatitis C. Combined with sofosbuvir; preferred backbone for genotype 3.
✓ Verificat medical de Morgan Ellis — Cercetător farmaceutic · 8 ani de experiență · Ultima recenzie: mai 2026
Răspuns rapid
Natdac — daclatasvir 30/60 mg (Natco Pharma). Pan-genotypic NS5A inhibitor — used in combination with sofosbuvir to cure hepatitis C across genotypes 1-6, especially genotype 3 where it remains preferred. Generic of BMS Daklinza.
Ce beneficii oferă MedsBase:
- producător certificat WHO-GMP
- Ambalaj discret în plic simplu
- Livrare în toată lumea
- Evaluat de peste 1.400 de clienți (citește recenziile)
📦 Garanția de retransmitere: dacă comanda dvs. nu a ajuns în 20 de zile lucrătoare de la expediere, o retransmitem fără costuri suplimentare. Citește politica.
De ce să comanzi de la MedsBase
Natdac ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
All DAA Hep C therapies carry an FDA black-box warning for hepatitis B virus reactivation in patients co-infected with HCV + HBV (which can be fulminant and fatal). Test for HBsAg and HBV DNA before starting any DAA regimen. If HBV-positive, hepatology must manage co-treatment or prophylactic anti-HBV therapy.
How daclatasvir works
NS5A is a multifunctional HCV protein essential for viral RNA replication and assembly. Daclatasvir binds NS5A and disrupts both replication-complex formation and virion assembly. It is potent, pan-genotypic, and well-tolerated.
Daclatasvir is always given with sofosbuvir (or another nucleotide backbone) — never as monotherapy. The combination achieves SVR12 in ≥95% of patients across genotypes, including genotype 3 (where ledipasvir-based regimens are weaker).
Standard dose is 60 mg once daily. Reduce to 30 mg with strong CYP3A4 inhibitors; increase to 90 mg with moderate inducers (where unavoidable).
Treatment-duration table
| Population | Regim |
|---|---|
| Genotype 1 / 4 / 5 / 6, treatment-naive, no cirrhosis | 12 weeks (typically combined with NS5A inhibitor) |
| Genotype 2, no cirrhosis | 12 weeks (sofosbuvir + ribavirin or sofosbuvir + daclatasvir) |
| Genotype 3, no cirrhosis | 12 weeks sofosbuvir + daclatasvir (sofosbuvir + velpatasvir is pan-genotypic alternative) |
| Compensated cirrhosis (any genotype) | 12 weeks combination DAA + ribavirin in selected cases; 24 weeks if treatment-experienced |
Sustained virologic response at 12 weeks post-treatment (SVR12) is the marker of cure — achieved in ~95-99% of patients across modern DAA regimens.
Important drug interactions
| Medicament | Effect & action |
|---|---|
| Amiodarone + sofosbuvir | FDA warning — symptomatic bradycardia, deaths reported. Avoid combination. If unavoidable, in-hospital cardiac monitoring required. |
| PPIs (omeprazole, pantoprazole) | Reduce ledipasvir absorption (pH-dependent). Take ledipasvir-containing regimens with food and PPIs ≥4 hours apart, or use H2 blockers/antacids instead. Velpatasvir also pH-sensitive — same advice. |
| Rifampicin, rifabutin | Strong CYP3A4 + P-gp inducers — significantly reduce DAA levels. Avoid combination. |
| St John’s wort | CYP3A4 induction — reduces DAA levels and risks treatment failure. Avoid throughout therapy. |
| Phenytoin, carbamazepine, oxcarbazepine | Anticonvulsant inducers — significantly reduce DAA levels. Switch to non-inducing antiepileptic (lamotrigine, levetiracetam) before starting Hep C therapy. |
| Statins (rosuvastatin, atorvastatin) | Variable rises in statin levels. Use lowest dose; rosuvastatin generally avoided with sof+vel; atorvastatin acceptable at low dose. |
| Warfarin | INR can fluctuate as the liver recovers during DAA therapy. Monitor INR weekly until stable. |
| HIV antiretrovirals | Tenofovir + ledipasvir — increased tenofovir exposure; monitor renal function. Efavirenz reduces velpatasvir levels — avoid combination. HCV-HIV co-infection always needs ID/hepatology specialist input. |
Întrebări frecvente
What is the cure rate?
Modern DAA regimens achieve sustained virologic response (SVR12) — undetectable HCV RNA at 12 weeks post-treatment, considered cure — in 95-99% of patients across genotypes. Cirrhosis, prior treatment failure, and HCV/HIV co-infection slightly reduce response rates.
What is SVR12?
Sustained Virologic Response at 12 weeks post-treatment. After completing a 12-week DAA course, HCV RNA is checked at 12 weeks after the last dose. Undetectable = cure. Late relapse beyond SVR12 is <1%.
Will I need a follow-up test?
Yes. HCV RNA at the end of treatment + at 12 weeks post-treatment confirms SVR12. Liver biochemistry and FibroScan/imaging at 6-12 months in cirrhotic patients to assess regression. Even after cure, screen for hepatocellular carcinoma every 6 months if cirrhosis is established.
What about hepatitis B?
All DAAs carry an FDA black-box warning for HBV reactivation in HCV+HBV co-infected patients. Test HBsAg and HBV DNA before starting. If HBV-positive, hepatology must coordinate.
Pot consuma alcool?
Avoid alcohol throughout treatment and ideally for 6-12 months after. Active alcohol use does not preclude DAA therapy but worsens long-term liver outcomes regardless of HCV status.
Sarcină?
Sofosbuvir is FDA pregnancy category B (no human teratogenicity data; animal data reassuring). Most DAAs lack pregnancy data. Contraception during therapy is standard. Ribavirin (where used as adjunct) is strongly teratogenic — both partners must use contraception during ribavirin therapy and 6 months after.
Side effects?
Modern DAAs are generally well tolerated. Common: fatigue, headache, nausea, insomnia. Less common: rash, diarrhoea. Treatment-limiting side effects are rare.
Generic vs branded — does it matter?
Indian generic DAAs are manufactured under voluntary licences from Gilead (Sovaldi, Harvoni, Epclusa), AbbVie, and BMS. They are bioequivalent and have the same molecule. Multiple real-world studies (CT2, Plus-Asia) show equivalent SVR12 rates to branded products.
Drug interactions to watch?
Most important: amiodarone + sofosbuvir (bradycardia black-box), rifampicin (kills DAA levels), PPIs (reduce ledipasvir/velpatasvir), HIV ARV adjustments needed in co-infection. Always disclose all medications including herbal/OTC.
After cure — can I get HCV again?
Yes. SVR clears the current infection but does not provide future immunity. Re-infection through new exposures (IV drug use, unsafe medical procedures, MSM with HIV co-infection) is possible. Counsel on prevention and offer HCV RNA testing at any new risk exposure.
Natdac (daclatasvir 60 mg) is taken alongside sofosbuvir for several genotypes, but for genotypes 1, 4, 5 and 6 the single-tablet Hepcinat LP (sofosbuvir 400 mg + ledipasvir 90 mg) consolidates both agents and improves adherence over the two-tablet daily regimen.
Other Hepatitis C Medications
- MyHep — sofosbuvir 400 mg — combination partner for daclatasvir
- Hepcinat — sofosbuvir 400 mg — Natco brand
- Hepcvir — sofosbuvir 400 mg — Cipla brand
- Velpanat — sofosbuvir + velpatasvir — alternative pan-genotypic single tablet
- Ledifos — sofosbuvir + ledipasvir for genotypes 1, 4, 5, 6
More options in Hepatitis Medication
Clasificate în funcție de volumul recent de comenzi MedsBase — ce aleg alți clienți în această categorie.
| Concentrație | 30 mg, 60 mg |
|---|---|
| Cantitate | 28 Comprimat/e, 56 Comprimat/e, 84 Comprimat/e |
| Formă farmaceutică | Comprimat/e |
| Producător | Natco Pharma |
| Indicație | Hepatitis |
| Brand generic | Daclatasvir |
Natdac
Întrebări și răspunsuri
Natdac
Produse similare
Recenzii
Nu există recenzii încă